CA3062418A1 - Methodes de traitement de troubles oculaires avec des antagonistes d'aplnr et des inhibiteurs de vegf - Google Patents

Methodes de traitement de troubles oculaires avec des antagonistes d'aplnr et des inhibiteurs de vegf Download PDF

Info

Publication number
CA3062418A1
CA3062418A1 CA3062418A CA3062418A CA3062418A1 CA 3062418 A1 CA3062418 A1 CA 3062418A1 CA 3062418 A CA3062418 A CA 3062418A CA 3062418 A CA3062418 A CA 3062418A CA 3062418 A1 CA3062418 A1 CA 3062418A1
Authority
CA
Canada
Prior art keywords
antibody
aplnr
antagonist
antigen
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3062418A
Other languages
English (en)
Inventor
Jingtai Cao
Eunice CHEUNG
Ivan B. Lobov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3062418A1 publication Critical patent/CA3062418A1/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des méthodes de traitement, de prévention ou de réduction de la gravité d'une pathologie oculaire. Les méthodes de la présente invention consistent à administrer, à un sujet qui en a besoin, une composition thérapeutique comprenant un antagoniste d'APLNR tel qu'un anticorps anti-APLNR en association avec un antagoniste du facteur de croissance vasculaire endothélial (VEGF) (par exemple, l'aflibercept).
CA3062418A 2017-05-06 2018-05-04 Methodes de traitement de troubles oculaires avec des antagonistes d'aplnr et des inhibiteurs de vegf Pending CA3062418A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502621P 2017-05-06 2017-05-06
US62/502,621 2017-05-06
PCT/US2018/031255 WO2018208625A1 (fr) 2017-05-06 2018-05-04 Méthodes de traitement de troubles oculaires avec des antagonistes d'aplnr et des inhibiteurs de vegf

Publications (1)

Publication Number Publication Date
CA3062418A1 true CA3062418A1 (fr) 2018-11-15

Family

ID=62555166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3062418A Pending CA3062418A1 (fr) 2017-05-06 2018-05-04 Methodes de traitement de troubles oculaires avec des antagonistes d'aplnr et des inhibiteurs de vegf

Country Status (9)

Country Link
EP (1) EP3618876A1 (fr)
JP (1) JP7161494B2 (fr)
CN (1) CN110709104A (fr)
AU (1) AU2018266324B2 (fr)
CA (1) CA3062418A1 (fr)
EA (1) EA201992630A1 (fr)
IL (1) IL270267B1 (fr)
MX (1) MX2019012985A (fr)
WO (1) WO2018208625A1 (fr)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
WO2004081198A2 (fr) 2003-03-12 2004-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Procedes de modulation de l'angiogenese avec de compositions d'apeline
WO2006088650A2 (fr) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Methode de traitement de lesion oculaire par l'administration locale d'un inhibiteur de vegf
JP5216002B2 (ja) 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したvegfアンタゴニスト製剤
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2734546A1 (fr) 2011-07-18 2014-05-28 Amgen Inc. Protéines de liaison à antigène de l'apéline et leurs utilisations
EA033387B1 (ru) 2012-01-23 2019-10-31 Regeneron Pharma СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
JP6181152B2 (ja) 2012-04-11 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アペリン阻害剤としてのポリペプチドおよびその使用
JP5775851B2 (ja) 2012-06-27 2015-09-09 東京エレクトロン株式会社 塗布装置および塗布液充填方法
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
JP6525951B2 (ja) * 2013-03-14 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. アペリン融合タンパク質およびその使用
BR112016011401A2 (pt) * 2013-11-20 2017-09-26 Regeneron Pharma moduladores de aplnr e utilizações dos mesmos
CA2942940A1 (fr) 2014-03-20 2015-09-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de composes inhibant la signalisation d'apeline/apj/gp130 pour le traitement du cancer
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
WO2017053807A2 (fr) * 2015-09-23 2017-03-30 Genentech, Inc. Variants optimisés d'anticorps anti-vegf

Also Published As

Publication number Publication date
EP3618876A1 (fr) 2020-03-11
MX2019012985A (es) 2020-01-13
AU2018266324A1 (en) 2019-11-28
WO2018208625A1 (fr) 2018-11-15
KR20200004366A (ko) 2020-01-13
IL270267A (fr) 2019-12-31
EA201992630A1 (ru) 2020-04-29
JP2020518641A (ja) 2020-06-25
CN110709104A (zh) 2020-01-17
AU2018266324B2 (en) 2024-02-01
JP7161494B2 (ja) 2022-10-26
IL270267B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US11071780B2 (en) Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
US20230020514A1 (en) Methods for treating or preventing migraine headache
US9926369B2 (en) Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody
US11104730B2 (en) Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
JP2021515003A (ja) 体組成を変更するための方法
US11066474B2 (en) Anti-TrkB monoclonal antibodies and methods of use
AU2018266324B2 (en) Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
KR102667021B1 (ko) Aplnr 길항제 및 vegf 저해제를 이용한, 안 장애의 치료 방법
KR20230129467A (ko) 항-푸코실-gm1 항체를 사용하는 조합 요법
EA043390B1 (ru) Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
US20220127344A1 (en) Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
KR20220007086A (ko) T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체
TW202108621A (zh) 抗-sema3a抗體及其用於治療眼或眼部疾病之用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220822

EEER Examination request

Effective date: 20220822

EEER Examination request

Effective date: 20220822

EEER Examination request

Effective date: 20220822

EEER Examination request

Effective date: 20220822